Acquired genetic alterations in tumor cells dictate the development of high-risk neuroblastoma and clinical outcomes

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Khan, Faizan H ^a   Pandian, Vijayabaskar ^a   Ramraj, Satishkumar ^a   Natarajan, Mohan ^b   Aravindan, Sheeja ^c   Herman, Terence S ^a,c   Aravindan, Natarajan ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Stephenson Cancer Center   (United States)

Author keywords

Array CGH; Clinical outcomes; Genetic rearrangements; High risk aggressive neuroblastoma; Karyotyping; Tumor progression

Indexed keywords

CD1C ANTIGEN; E1A ASSOCIATED P300 PROTEIN; TRANSCRIPTION FACTOR FOXP2;

A4GALT GENE; ADAM5 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOBEC3B GENE; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; CD1C GENE; CELL CLONING; CFHR3 GENE; CHROMOSOME 15Q; CHROMOSOME 1Q; CHROMOSOME 22Q; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME 9Q; CHROMOSOME DELETION; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CSMD3 GENE; CYTOGENETICS; EP300 GENE; EX VIVO STUDY; FOXP2 GENE; GENE; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HIGH RISK NEUROBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VIVO STUDY; KARYOTYPING; L3MBTL2 GENE; LOC100288142 GENE; LOC400927 GENE; MAL2 GENE; MDFIC GENE; METASTATIC SITE DERIVED AGGRESSIVE CELL; MGAT3 GENE; MICROARRAY ANALYSIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; POLDIP3 GENE; POLYMERASE CHAIN REACTION; RALYL GENE; RECURRENCE FREE SURVIVAL; RPL3 GENE; SAMD12 AS1 GENE; SERHL GENE; SH SY5Y CELL LINE; SLC25A17 GENE; TRISOMY; TTLL1 GENE; TUMOR CELL; ANIMAL; CANCER STAGING; CANCER STEM CELL; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; DISEASE COURSE; DISEASE MODEL; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOME BANDING; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; GENETIC ASSOCIATION STUDIES; HETEROGRAFTS; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PROGNOSIS;

EID: 84936771053     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1463-y     Document Type: Article

References (43)

1. Latimer E, Anderson G, Sebire NJ. Ultrastructural features of neuroblastic tumours in relation to morphological, and molecular findings; a retrospective review study. BMC clinical pathology. 2014;14:13.
2. Weinstein JL, Katzenstein HM, Cohn SL. Advances in the diagnosis and treatment of neuroblastoma. The oncologist. 2003;8(3):278-92.
3. Chen CY, Chiou SH, Huang CY, Jan CI, Lin SC, Tsai ML, et al. Distinct population of highly malignant cells in a head and neck squamous cell carcinoma cell line established by xenograft model. J Biomed Sci. 2009;16:100.
4. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165-73.
5. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24(18):2891-6.
6. Garaventa A, Parodi S, De Bernardi B, Dau D, Manzitti C, Conte M, et al. Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur J Cancer. 2009;45(16):2835-42.
7. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011;29(24):3286-92.
8. Caldas C. Cancer sequencing unravels clonal evolution. Nature biotechnology. 2012;30(5):408-10.
9. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506-10.
10. Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471-82.
11. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007;2(2), e255.
12. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J, Pierron G, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010;28(19):3122-30.
13. Schleiermacher G, Michon J, Ribeiro A, Pierron G, Mosseri V, Rubie H, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105(12):1940-8.
14. Stallings RL. Origin and functional significance of large-scale chromosomal imbalances in neuroblastoma. Cytogenet Genome Res. 2007;118(2-4):110-5.
15. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst. 1983;71(4):741-7.
16. Spengler BA, Biedler JL, Ross RA. A corrected karyotype for the SH-SY5Y human neuroblastoma cell line. Cancer Genet Cytogenet. 2002;138(2):177-8.
17. Van Roy N, Van Limbergen H, Vandesompele J, Van Gele M, Poppe B, Salwen H, et al. Combined M-FISH and CGH analysis allows comprehensive description of genetic alterations in neuroblastoma cell lines. Genes Chromosomes Cancer. 2001;32(2):126-35.
18. Do JH, Kim IS, Park TK, Choi DK. Genome-wide examination of chromosomal aberrations in neuroblastoma SH-SY5Y cells by array-based comparative genomic hybridization. Mol Cells. 2007;24(1):105-12.
19. Kryh H, Caren H, Erichsen J, Sjoberg RM, Abrahamsson J, Kogner P, et al. Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC genomics. 2011;12:443.
20. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203-16.
21. Spitz R, Oberthuer A, Zapatka M, Brors B, Hero B, Ernestus K, et al. Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome. Genes Chromosomes Cancer. 2006;45(12):1130-42.
22. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-97.
23. Joshua BZ, Sachs O, Shelef I, Vardy-Sion N, Novack L, Vaiman M, et al. Comparison of clinical data, CT, and bone histopathology in unilateral chronic maxillary sinusitis. Otolaryngol Head Neck Surg. 2013;148(1):145-50.
24. Santana VM, Furman WL, McGregor LM, Billups CA. Disease control intervals in high-risk neuroblastoma. Cancer. 2008;112(12):2796-801.
25. Simon T, Berthold F, Borkhardt A, Kremens B, De Carolis B, Hero B. Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials. Pediatric blood & cancer. 2011;56(4):578-83.
26. Veeraraghavan J, Natarajan M, Aravindan S, Herman TS, Aravindan N. Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells. J Biol Chem. 2011;286(24):21588-600.
27. Khan FH, Pandian V, Ramraj S, Aravindan S, Herman TS and Aravindan N. Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics. 2015;16:501 doi: 10.1186/s12864-015-1642-x .
28. Pandian V, Ramraj S, Khan FH, Azim T and Aravindan N. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. Stem Cell Research & Therapy. 2015;6(1):2. doi: 10.1186/s13287-015-0002-8 .
29. Khan FH, Ganesan P, Kumar S. Y Chromosome microdeletion and altered sperm quality in human males with high concentration of seminal hexachlorocyclohexane (HCH). Chemosphere. 2010;80(9):972-7.
30. Aravindan N, Madhusoodhanan R, Ahmad S, Johnson D, Herman TS. Curcumin inhibits NFkappaB mediated radioprotection and modulate apoptosis related genes in human neuroblastoma cells. Cancer Biol Ther. 2008;7(4):569-76.
31. Aravindan S, Natarajan M, Awasthi V, Herman TS, Aravindan N. Novel synthetic monoketone transmute radiation-triggered NFkappaB-dependent TNFalpha cross-signaling feedback maintained NFkappaB and favors neuroblastoma regression. PLoS One. 2013;8(8), e72464.
32. Kovalevich J, Langford D. Considerations for the use of SH-SY5Y neuroblastoma cells in neurobiology. Methods Mol Biol. 2013;1078:9-21.
33. Yokota J. Tumor progression and metastasis. Carcinogenesis. 2000;21(3):497-503.
34. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature. 1983;305(5937):779-84.
35. Land H, Parada LF, Weinberg RA. Cellular oncogenes and multistep carcinogenesis. Science. 1983;222(4625):771-8.
36. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 2008;75(2):75-84.
37. Nicolson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 1987;47(6):1473-87.
38. Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol Med. 1998;4(5):286-95.
39. Sandberg AA, Meloni-Ehrig AM. Cytogenetics and genetics of human cancer: methods and accomplishments. Cancer Genet Cytogenet. 2010;203(2):102-26.
40. Chen K, Huang YH, Chen JL. Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013;34(6):732-40.
41. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69(4):1302-13.
42. Fidler IJ. Selection of successive tumour lines for metastasis. Nat New Biol. 1973;242(118):148-9.
43. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res. 1990;50(19):6130-8.